Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDr. Martens Regulatory News (DOCS)

Share Price Information for Dr. Martens (DOCS)

Share Price is delayed by 15 minutes
Get Live Data
71.50    0.50 (0.70%)
Bid:
71.20
Ask:
74.00
Spread: 2.80 (3.933%)
Market Cap: £684.32m
DOCS Live PriceLast checked at - London Stock Exchange

Intraday Dr. Martens Share Chart

Chief Brand Officer Appointment

16 Nov 2023 07:00

RNS Number : 6029T
Dr. Martens PLC
16 November 2023
Β 

16 November 2023

Dr. Martens plc

Creation of Chief Brand Officer role

Ije Nwokorie appointed into new role and will step down as Non-Executive Director as a result

Β 

Dr. Martens plc announces that Non-Executive Director Ije Nwokorie will join as Chief Brand Officer from 1st February 2024. On appointment into this role, Ije will cease to be a member of the Board and will step down as a member of the Audit and Risk, Nomination and Disclosure committees.

The newly-created role of Chief Brand Officer will be a key member of the global leadership team, reporting into Kenny Wilson, CEO, overseeing the Global Marketing, Product and Strategy functions. The Chief Brand Officer will be responsible for setting the overall brand strategy, vision and direction for the next phase of Dr. Martens' growth.

Ije will join Dr. Martens as Chief Brand Officer from Apple Inc, where he has been Senior Director, Apple Retail since January 2018. Prior to this he spent 11 years at global brand consultancy Wolff Olins, where he was latterly CEO, leading teams in offices in San Francisco, London, Dubai and New York. He is currently also Chair of non-profit organisation charity: water UK.

Paul Mason, Chair, said "Ije has been a tremendous Non-Executive Director since he joined the Board in January 2021. He has deep insight and understanding of brands and has extensive global DTC experience. I am delighted that he'll be joining the leadership team as Chief Brand Officer, a role for which he is perfectly suited."

Kenny Wilson, CEO, said "Ije is a visionary brand storyteller and this, along with his infectious passion for Dr. Martens, makes him the ideal person to lead the next era of our brand development. I am delighted that he will be joining my team in a permanent full-time position of Chief Brand Officer, which will be a crucial role to enable us to become a Β£2bn revenue brand."

Ije Nwokorie said "I've always loved Dr. Martens and it's been a real privilege getting to know the brand from the inside as a Non-Executive Director. Dr. Martens is defined by its rebellious, authentic and creative nature, all of which makes me really excited to be joining Kenny and the team early in the new year and to get to work."

Β 

Enquiries

Investors and analysts

Bethany Barnes, Director of Investor Relations Bethany.Barnes@drmartens.com +44 7825 187465

Beth Callum, Senior Investor Relations Analyst Beth.Callum@drmartens.com +44 203 995 2644

Β 

Press

H/Advisors Maitland +44 207 379 5151

Clinton Manning +44 7711 972662

Β 

Gill Hammond, Director of Communications +44 7384 214248

Β 

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Produced originally for workers looking for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical movements. Dr. Martens has since transcended its working-class roots while still celebrating its proud heritage and, six decades later, "Docs" or "DM's" are worn by people around the world who use them as a symbol of empowerment and their own individual attitude. The Company is a constituent of the FTSE 250 index.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
RDNBLBDBGUBDGXU
Date   Source Headline
8th Jun 202612:26 pmRNSHolding(s) in Company
5th Jun 202610:43 amRNSAdmission to Trading
2nd Jun 20269:00 amRNSDirector/PDMR Shareholding
2nd Jun 20269:00 amRNSAnnual Financial Report
2nd Jun 20268:22 amRNSTotal Voting Rights
27th May 20267:00 amRNSDirectorate change
19th May 20267:00 amRNSEBT Share Purchase
19th May 20267:00 amRNSFY26 Results
14th May 20268:53 amRNSDirector/PDMR Shareholding
1st May 20267:00 amRNSHolding(s) in Company
30th Apr 20268:31 amRNSTotal Voting Rights
29th Apr 20267:00 amRNSHolding(s) in Company
16th Apr 20267:00 amRNSDirector/PDMR Shareholding
15th Apr 20269:50 amRNSDirector/PDMR Shareholding
10th Apr 20261:46 pmRNSDirector/PDMR Shareholding
8th Apr 20267:00 amRNS-RAppointment of Market General Managers
31st Mar 20269:53 amRNSTotal Voting Rights
20th Mar 20267:00 amRNSHolding(s) in Company
13th Mar 20262:03 pmRNSDirector/PDMR Shareholding
27th Feb 202611:04 amRNSTotal Voting Rights
13th Feb 202610:49 amRNSDirector/PDMR Shareholding
30th Jan 202611:15 amRNSTotal Voting Rights
29th Jan 20267:00 amRNSEBT Share Purchase
27th Jan 20267:00 amRNSHolding(s) in Company
27th Jan 20267:00 amRNSQ3 FY26 Trading Statement
15th Jan 20269:24 amRNSDirector/PDMR Shareholding
31st Dec 202511:11 amRNSTotal Voting Rights
31st Dec 202511:11 amRNSTotal Voting Rights
12th Dec 20253:00 pmRNSDirector/PDMR Shareholding
12th Dec 20257:00 amRNSDirector/PDMR Shareholding
8th Dec 20257:00 amRNSDirector/PDMR Shareholding
1st Dec 202512:35 pmRNSBlock listing Interim Review
28th Nov 202511:58 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSHolding(s) in Company
20th Nov 20257:00 amRNSH1 FY26 Results
12th Nov 20252:13 pmRNSDirector/PDMR Shareholding
31st Oct 20252:37 pmRNSTotal Voting Rights
21st Oct 20256:16 pmRNSHolding(s) in Company
20th Oct 20254:06 pmRNSHolding(s) in Company
16th Oct 20252:12 pmRNSDirector/PDMR Shareholding
14th Oct 202511:51 amRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSAppointment of joint corporate broker
9th Oct 20251:53 pmRNSDirector/PDMR Shareholding
2nd Oct 20254:20 pmRNSTotal Voting Rights
2nd Oct 20257:00 amRNS-RUAE distribution partnership and LATAM expansion
16th Sep 202511:55 amRNSDirector/PDMR Shareholding
16th Sep 20257:00 amRNSHolding(s) in Company
2nd Sep 20259:30 amRNSDirector/PCA Shareholding
29th Aug 20254:22 pmRNSTotal Voting Rights
12th Aug 20253:17 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.